MTOR and neoplasm: The first pNET PDX model was reported in 2018 by Chamberlain et al. This was isolated and expanded using tissue obtained from a patient with metastatic insulinoma to the liver, and it was used to test the antitumour effect of the mTOR inhibitor sapanisertib in everolimus-resistant tumours [40].